Male Hypogonadism - Pipeline Review, H1 2017

Published: Feb, 2017 | Pages: 104 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism - Pipeline Review, H1 2017, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 1, 4, 7, 2, 1 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
- The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Male Hypogonadism - Overview
Male Hypogonadism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Male Hypogonadism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Male Hypogonadism - Companies Involved in Therapeutics Development
Antares Pharma Inc
Clarus Therapeutics Inc
EndoCeutics Inc
Ferring International Center SA
IASO BioMed Inc
Lipocine Inc
M et P Pharma AG
Medlab Clinical Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
Pantarhei Bioscience BV
Repros Therapeutics Inc
Takeda Pharmaceutical Company Ltd
TesoRx Pharma LLC
Viramal Ltd
Male Hypogonadism - Drug Profiles
BGS-649 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corifollitropin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enclomiphene citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IAS-167A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kisspeptin-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LPCN-1111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSS-722 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-448 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone enanthate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone propionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Male Hypogonadism - Dormant Projects
Male Hypogonadism - Discontinued Products
Male Hypogonadism - Product Development Milestones
Featured News & Press Releases
Feb 08, 2017: Acerus Announces NATESTO Posters to Be Presented at the Endocrine Society 2017 Annual Meeting
Feb 01, 2017: Aytu BioScience Announces Two Presentations at Endocrine Society 2017 Annual Meeting Highlighting Benefits of Natesto (Testosterone) Nasal Gel in Men
Jan 24, 2017: Acerus Announces Natesto Abstracts To Be Presented At The American Urological Associations Annual Meeting
Jan 18, 2017: Aytu BioScience Announces Two Presentations Highlighting Benefits of Natesto (Testosterone) Nasal Gel in Men at American Urological Association Annual Meeting
Dec 21, 2016: Antares Pharma Announces Submission of New Drug Application for Quickshot Testosterone
Dec 06, 2016: FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism
Nov 30, 2016: Aytu BioScience Announces Study Findings Demonstrating Clinical Improvements in Erectile Function and Mood in Hypogonadal Men Treated with Natesto Nasal Testosterone Gel
Nov 21, 2016: Diurnal Group: First patient dosed in testosterone replacement therapy for hypogonadism
Nov 02, 2016: Antares Pharma Announces Presentations at the Sexual Medicine Society Scientific Annual Meeting
Oct 28, 2016: Antares Pharma Announces Multiple Presentations at the Sexual Medicine Society Scientific Annual Meeting
Oct 05, 2016: Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities
Oct 05, 2016: Acerus Announces Canadian Commercial Launch of NATESTO
Sep 26, 2016: Lipocine Announces Positive Top-Line Phase 2b Study Results for LPCN 1111, a Next Generation Oral Testosterone Replacement Therapy
Sep 22, 2016: Antares Pharma Announces Completion of the QuickShot Testosterone Clinical Program
Sep 12, 2016: Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Male Hypogonadism, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Male Hypogonadism - Pipeline by Antares Pharma Inc, H1 2017
Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H1 2017
Male Hypogonadism - Pipeline by EndoCeutics Inc, H1 2017
Male Hypogonadism - Pipeline by Ferring International Center SA, H1 2017
Male Hypogonadism - Pipeline by IASO BioMed Inc, H1 2017
Male Hypogonadism - Pipeline by Lipocine Inc, H1 2017
Male Hypogonadism - Pipeline by M et P Pharma AG, H1 2017
Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H1 2017
Male Hypogonadism - Pipeline by Merck & Co Inc, H1 2017
Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H1 2017
Male Hypogonadism - Pipeline by Pantarhei Bioscience BV, H1 2017
Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H1 2017
Male Hypogonadism - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H1 2017
Male Hypogonadism - Pipeline by Viramal Ltd, H1 2017
Male Hypogonadism - Dormant Projects, H1 2017
Male Hypogonadism - Discontinued Products, H1 2017